Li Yin,Jiang-Jie Duan,Xiu-Wu Bian et al.
Li Yin et al.
Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER-2), has clinical features that include high...
Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women [0.03%]
黑人女性和白人女性乳腺肿瘤中CD8+T细胞浸润的差异
Yara Abdou,Kristopher Attwood,Ting-Yuan David Cheng et al.
Yara Abdou et al.
Background: African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been...
Multicenter Study
Breast cancer research : BCR. 2020 Jun 9;22(1):62. DOI:10.1186/s13058-020-01297-4 2020
Enhanced mitochondrial fission suppresses signaling and metastasis in triple-negative breast cancer [0.03%]
增强的线粒体分裂可抑制三阴性乳腺癌的信号传导和转移
Brock A Humphries,Alyssa C Cutter,Johanna M Buschhaus et al.
Brock A Humphries et al.
Background: Mitochondrial dynamics underlies malignant transformation, cancer progression, and response to treatment. Current research presents conflicting evidence for functions of mitochondrial fission and fusion in tum...
FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors [0.03%]
泛素连接酶FBW9促进三阴性乳腺癌的发生发展
Ritama Paul,Ming Luo,Xueying Mo et al.
Ritama Paul et al.
Background: Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast can...
Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer [0.03%]
超快速对比增强乳腺MRI可以产生乳腺癌预后影像标志物
Natsuko Onishi,Meredith Sadinski,Mary C Hughes et al.
Natsuko Onishi et al.
Background: Ultrafast dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)-derived kinetic parameters have demonstrated at least equivalent accuracy to standard DCE-MRI in differentiating malignant from benign b...
Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer [0.03%]
绝经后ER阳性转移性乳腺癌一线使用AI治疗过程中，循环ESR1突变、CA15.3和cfDNA增加提示早期进展风险：IMpassion062研究的子集分析
Florian Clatot,Anne Perdrix,Ludivine Beaussire et al.
Florian Clatot et al.
Background: Endocrine therapy is recommended as a first-line treatment for hormone receptor-positive metastatic breast cancer (HR+MBC) patients. No biomarker has been validated to predict tumor progression in that setting...
Observational Study
Breast cancer research : BCR. 2020 May 28;22(1):56. DOI:10.1186/s13058-020-01290-x 2020
A machine learning model that classifies breast cancer pathologic complete response on MRI post-neoadjuvant chemotherapy [0.03%]
一种基于MRI的机器学习模型，用于对新辅助化疗后的乳腺癌病理完全缓解进行分类
Elizabeth J Sutton,Natsuko Onishi,Duc A Fehr et al.
Elizabeth J Sutton et al.
Background: For breast cancer patients undergoing neoadjuvant chemotherapy (NAC), pathologic complete response (pCR; no invasive or in situ) cannot be assessed non-invasively so all patients undergo surgery. The aim of ou...
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area [0.03%]
新型冠状病毒肺炎在乳腺癌患者中的临床特征——巴黎居里研究所的病例报告
Perrine Vuagnat,Maxime Frelaut,Toulsie Ramtohul et al.
Perrine Vuagnat et al.
Background: Cancer patients have been reported to be at higher risk of COVID-19 complications and deaths. We report the characteristics and outcome of patients diagnosed with COVID-19 during breast cancer treatment at Ins...
Modeling the natural history of ductal carcinoma in situ based on population data [0.03%]
基于人群数据的导管原位癌自然病史模型
Sarocha Chootipongchaivat,Nicolien T van Ravesteyn,Xiaoxue Li et al.
Sarocha Chootipongchaivat et al.
Background: The incidence of ductal carcinoma in situ (DCIS) has increased substantially since the introduction of mammography screening. Nevertheless, little is known about the natural history of preclinical DCIS in the ...
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer [0.03%]
绝经前患者雌激素受体阳性、HER2阴性淋巴结阳性乳腺癌新辅助内分泌治疗与化疗疗效的对比研究
Hee Jeong Kim,Woo Chul Noh,Eun Sook Lee et al.
Hee Jeong Kim et al.
Introduction: Neoadjuvant endocrine therapy (NET) has demonstrated efficacy in post-menopausal patients with hormone-responsive breast cancer. This trial was designed to compare the efficacy of neoadjuvant chemotherapy (N...